Insights
Search Results
Client Highlights
3.31.26
Wilson Sonsini Advises Helix Earth on $12 Million Seed 2 Funding
On March 26, 2026, Helix Earth, a hardware company built on proprietary liquid-gas chemistry with roots in NASA aerospace technology, announced the successful close of its $12 million oversubscribed Seed 2 funding. The oversubscribed financing round was led by Veriten, with participation from Rua Ventures, Carnrite Ventures, Skywriter LLC, Textbook Ventures, and others. Wilson Sonsini Goodrich & Rosati advised Helix Earth on the transaction and WS Investments participated in the round.
Client Highlights
2.13.26
Firm Advises Microchip Technology on Offering of $900 Million of Convertible Senior Notes
On February 11, 2026, Microchip Technology completed an offering of $900 million aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Microchip had granted to the initial purchasers to purchase up to an additional $100 million of notes. In connection with the offering, Microchip entered into privately negotiated capped call transactions with certain of the initial purchasers or their respective affiliates and other financial institutions.
Client Highlights
7.10.25
Wilson Sonsini Represents Tenstorrent in Acquisition of Blue Cheetah
On July 1, 2025, Tenstorrent, a next-generation computing company building computers for AI, announced that it had acquired Blue Cheetah Analog Design, a startup specializing in highly customized analog mixed-signal IP. Wilson Sonsini Goodrich & Rosati advised Tenstorrent on the transaction.
News Articles
6.05.25
2025 Chambers USA Guide Recognizes Wilson Sonsini Practices, Attorneys
The 2025 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 39 geography-specific practice categories and named 86 Wilson Sonsini attorneys among the best in their fields. This year, the firm received three new practice area rankings, including in the Artificial Intelligence category, and four improved practice area rankings.
Client Highlights
5.28.25
Wilson Sonsini Advises Placement Agent on $200 Million Convertible Preferred Stock Offering for Luminar Technologies
On May 21, 2025, Luminar Technologies, a leading global automotive technology company, announced it has entered into a definitive agreement to issue up to $200 million of convertible preferred stock to YA II PN, Ltd. and another accredited investor over an 18-month period. Wilson Sonsini Goodrich & Rosati advised D. Boral Capital as the exclusive placement agent on the transaction.
Client Highlights
3.25.25
Wilson Sonsini Advises Microchip on Offering of $1.48 Billion of Depositary Shares
On March 25, 2025, Microchip Technology completed a mandatory convertible preferred stock offering of $1.48 billion of depositary shares, each representing a 1/20th interest in a share of 7.50% Series A Mandatory Convertible Preferred Stock, in an underwritten public offering. The offering amount included the exercise in full of the over-allotment option that Microchip had granted to the underwriters to purchase up to an additional $135 million of depositary shares. In connection with the offering, Microchip entered into privately negotiated capped call transactions with one or more of the underwriters and other financial institutions. Microchip is one of the first technology companies to use this mandatory convertible preferred stock structure with a capped call feature.
Client Highlights
1.14.25
Wilson Sonsini Advises Alleviant Medical on $90 Million Financing
On January 14, 2025, Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, announced a $90 million financing to fund its second pivotal trial. Led by Glide Healthcare, the round also adds Omega Funds and includes participation from existing shareholders S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Venture Fund, and undisclosed strategic investors. Wilson Sonsini Goodrich & Rosati advised Alleviant on the transaction.
The new pivotal trial, ALLAY-HFrEF, will be the first prospective sham-controlled trial focused on patients with heart failure and reduced ejection fraction (HFrEF) in the atrial shunt space. Alleviant will be the only atrial shunt company to have ongoing clinical trials for the full spectrum of heart failure. The company’s first pivotal trial (ALLAY-HF), evaluating the Alleviant System’s safety and efficacy in patients with heart failure and preserved ejection fraction (HFpEF), is on track to finalize enrollment within the next year. The new trial will expand investigation to patients with the other primary form of heart failure, those with reduced ejection fraction (HFrEF).
The Wilson Sonsini team advising Alleviant on the financing was led by Rob Suffoletta and included Nathan Robinson, Alex Dolphin, and Tanner Kuenneth.
For more information, please see Alleviant’s news release.
The new pivotal trial, ALLAY-HFrEF, will be the first prospective sham-controlled trial focused on patients with heart failure and reduced ejection fraction (HFrEF) in the atrial shunt space. Alleviant will be the only atrial shunt company to have ongoing clinical trials for the full spectrum of heart failure. The company’s first pivotal trial (ALLAY-HF), evaluating the Alleviant System’s safety and efficacy in patients with heart failure and preserved ejection fraction (HFpEF), is on track to finalize enrollment within the next year. The new trial will expand investigation to patients with the other primary form of heart failure, those with reduced ejection fraction (HFrEF).
The Wilson Sonsini team advising Alleviant on the financing was led by Rob Suffoletta and included Nathan Robinson, Alex Dolphin, and Tanner Kuenneth.
For more information, please see Alleviant’s news release.
Client Highlights
12.16.24
Wilson Sonsini Represents Microchip in $2 Billion Investment Grade Notes Offering
On December 16, 2024, Microchip Technology Incorporated (Microchip) priced an offering of (i) $1 billion in aggregate principal amount of its 4.900 percent senior notes due 2028 (2028 notes), and (ii) $1 billion in aggregate principal amount of its 5.050 percent senior notes due 2030 (2030 notes, together with 2028 notes, “the notes”). The notes are and will be guaranteed by each of Microchip's existing and future subsidiaries that is or becomes an obligor under Microchip's existing senior credit facilities. The sale of the notes closed on December 16, 2024. Microchip intends to use the net proceeds from the sale of the notes to repay its senior term loan facility, a portion of the debt outstanding under its commercial paper program and the payment of fees and expenses related to the offering of the notes.
Client Highlights
12.13.24
Wilson Sonsini Advises Lumos Pharma on Tender Offer and Merger with Double Point Ventures
On December 12, 2024, Lumos Pharma, a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures (DPV) announced the successful completion the previously announced tender offer for Lumos Pharma's shares, with 75.62 percent of shares tendered. The purchase price of $4.25 per share represents a total equity value of approximately $38 million. Following the acceptance of the shares offered in the tender, DPV successfully acquired enough shares of Lumos Pharma's common stock to finalize the merger. Wilson Sonsini Goodrich & Rosati advised Lumos Pharma on the transaction.
Client Highlights
12.04.24
Wilson Sonsini Advises Tenstorrent on $693 Million Series D Financing
On December 2, 2024, Tenstorrent, a next-generation computing company that builds computers for AI, announced the closing of over $693 million in its Series D funding round, at a pre-money valuation of $2 billion. Samsung Securities and AFW Partners led the round, with participation from XTX Markets, Corner Capital, MESH, Export Development Canada, Healthcare of Ontario Pension Plan, LG Electronics, Hyundai Motor Group, Fidelity Management & Research Company, Baillie Gifford, Bezos Expeditions, and more. Wilson Sonsini Goodrich & Rosati advised Tenstorrent on the transaction.
News Articles
8.08.24
IFLR1000 Recognizes Wilson Sonsini Practices, Attorneys in 2024 Guide
In the 2024 edition of its annual guide, IFLR recognized Wilson Sonsini practices and attorneys for their work in the financial and corporate sectors in the U.S. and China. The guide uses in-depth market analysis and interviews with practitioners and clients to determine leading financial and corporate law firms worldwide. Wilson Sonsini’s rankings are summarized below.
Client Highlights
7.12.24
Wilson Sonsini Advises Seismos on $15 Million Growth Investment Led by Edison Partners
On July 10, 2024, Seismos, Inc., a leader in AI-powered Acoustic Sensing, and growth equity firm Edison Partners announced a $15 million growth investment to enable and accelerate the energy industry’s shift from analog-focused exploration and production to technology-driven, digital infrastructure, and autonomous production operations. Wilson Sonsini Goodrich & Rosati advised Seismos on the transaction.